These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-000557-35 A phase II, multi centre, pilot, randomised, ascending dose, double -blind, placebo controlled, dose titration study to determine the safety, maximum tolerated dose and preliminary evidence of efficac... not-yet-due
Ongoing 2004-000833-12 A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients wit... not-yet-due
Listed as ongoing, but also has a completion date 2004-000835-27 A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early ... 2007-01-29 bad-data
Not reported 2006-005860-14 A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic p... 2008-10-30 due-trials
Not reported 2006-005861-21 A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERA... 2010-04-29 due-trials
Listed as ongoing, but also has a completion date 2007-002963-28 A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with ... 2012-03-06 bad-data
Listed as ongoing, but also has a completion date 2007-002964-90 A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic P... 2012-03-29 bad-data
Listed as ongoing, but also has a completion date 2008-004146-88 A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects w... 2012-06-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005492-94 Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients 2012-07-13 bad-data
Not reported 2008-006159-39 A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, EXTENSION STUDY TO ASSESS LONG-TERM SAFETY AND EFFICACY OF TWO FIXED DOSES OF RALFINAMIDE (160 OR 320 MG/DAY) IN PATIENTS WITH CHRONIC NEUR... 2010-06-22 due-trials
Not reported 2008-006176-30 EFFICACY AND SAFETY OF TWO FIXED DOSES (160 OR 320 MG/DAY) OF RALFINAMIDE IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN. A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED 12- WEEK STUDY... 2010-03-11 due-trials
Ongoing 2015-004448-20 A Randomized, Double-Blind, Placebo-Controlled, Six-Month Study to Evaluate the Efficacy, Safety and Tolerability of Sarizotan in Patients with Rett Syndrome with Respiratory Symptoms not-yet-due